Sophia Genetics Sa Stock Net Income
| SOPH Stock | USD 5.36 0.16 2.90% |
As of the 25th of January, Sophia Genetics has the Semi Deviation of 3.06, risk adjusted performance of 0.085, and Coefficient Of Variation of 954.77. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sophia Genetics SA, as well as the relationship between them.
Sophia Genetics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 4.7127 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -56.2 M | -59.1 M | |
| Net Loss | -78.7 M | -82.6 M | |
| Net Loss | -55.1 M | -57.9 M | |
| Net Loss | (1.09) | (1.15) | |
| Net Income Per E B T | 0.92 | 0.80 |
Sophia | Net Income | Build AI portfolio with Sophia Stock |
Latest Sophia Genetics' Net Income Growth Pattern
Below is the plot of the Net Income of Sophia Genetics SA over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Sophia Genetics SA financial statement analysis. It represents the amount of money remaining after all of Sophia Genetics SA operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Sophia Genetics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sophia Genetics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (61.27 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Sophia Net Income Regression Statistics
| Arithmetic Mean | (46,773,329) | |
| Coefficient Of Variation | (40.15) | |
| Mean Deviation | 16,147,955 | |
| Median | (33,791,000) | |
| Standard Deviation | 18,781,439 | |
| Sample Variance | 352.7T | |
| Range | 53.7M | |
| R-Value | (0.73) | |
| Mean Square Error | 177.5T | |
| R-Squared | 0.53 | |
| Significance | 0.001 | |
| Slope | (2,703,015) | |
| Total Sum of Squares | 5643.9T |
Sophia Net Income History
Other Fundumenentals of Sophia Genetics SA
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Sophia Genetics Net Income component correlations
Sophia Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Sophia Genetics is extremely important. It helps to project a fair market value of Sophia Stock properly, considering its historical fundamentals such as Net Income. Since Sophia Genetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sophia Genetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sophia Genetics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sophia Genetics. If investors know Sophia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sophia Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share | Quarterly Revenue Growth 0.228 | Return On Assets | Return On Equity |
The market value of Sophia Genetics SA is measured differently than its book value, which is the value of Sophia that is recorded on the company's balance sheet. Investors also form their own opinion of Sophia Genetics' value that differs from its market value or its book value, called intrinsic value, which is Sophia Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sophia Genetics' market value can be influenced by many factors that don't directly affect Sophia Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sophia Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sophia Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sophia Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Sophia Genetics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Sophia Genetics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Sophia Genetics.
| 10/27/2025 |
| 01/25/2026 |
If you would invest 0.00 in Sophia Genetics on October 27, 2025 and sell it all today you would earn a total of 0.00 from holding Sophia Genetics SA or generate 0.0% return on investment in Sophia Genetics over 90 days. Sophia Genetics is related to or competes with Simulations Plus, Definitive Healthcare, Kindly MD, Alto Neuroscience, Cellectis, National Research, and OPTIMIZERx Corp. SOPHiA GENETICS SA operates as a healthcare technology company More
Sophia Genetics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Sophia Genetics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Sophia Genetics SA upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.42 | |||
| Information Ratio | 0.0872 | |||
| Maximum Drawdown | 22.25 | |||
| Value At Risk | (6.03) | |||
| Potential Upside | 7.05 |
Sophia Genetics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sophia Genetics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Sophia Genetics' standard deviation. In reality, there are many statistical measures that can use Sophia Genetics historical prices to predict the future Sophia Genetics' volatility.| Risk Adjusted Performance | 0.085 | |||
| Jensen Alpha | 0.3645 | |||
| Total Risk Alpha | 0.041 | |||
| Sortino Ratio | 0.1143 | |||
| Treynor Ratio | 0.3316 |
Sophia Genetics January 25, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.085 | |||
| Market Risk Adjusted Performance | 0.3416 | |||
| Mean Deviation | 3.31 | |||
| Semi Deviation | 3.06 | |||
| Downside Deviation | 3.42 | |||
| Coefficient Of Variation | 954.77 | |||
| Standard Deviation | 4.48 | |||
| Variance | 20.07 | |||
| Information Ratio | 0.0872 | |||
| Jensen Alpha | 0.3645 | |||
| Total Risk Alpha | 0.041 | |||
| Sortino Ratio | 0.1143 | |||
| Treynor Ratio | 0.3316 | |||
| Maximum Drawdown | 22.25 | |||
| Value At Risk | (6.03) | |||
| Potential Upside | 7.05 | |||
| Downside Variance | 11.7 | |||
| Semi Variance | 9.38 | |||
| Expected Short fall | (4.09) | |||
| Skewness | 1.21 | |||
| Kurtosis | 2.75 |
Sophia Genetics SA Backtested Returns
Sophia Genetics appears to be moderately volatile, given 3 months investment horizon. Sophia Genetics SA owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.11, which indicates the firm had a 0.11 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Sophia Genetics SA, which you can use to evaluate the volatility of the company. Please review Sophia Genetics' Risk Adjusted Performance of 0.085, semi deviation of 3.06, and Coefficient Of Variation of 954.77 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Sophia Genetics holds a performance score of 8. The entity has a beta of 1.38, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Sophia Genetics will likely underperform. Please check Sophia Genetics' value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Sophia Genetics' existing price patterns will revert.
Auto-correlation | 0.46 |
Average predictability
Sophia Genetics SA has average predictability. Overlapping area represents the amount of predictability between Sophia Genetics time series from 27th of October 2025 to 11th of December 2025 and 11th of December 2025 to 25th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Sophia Genetics SA price movement. The serial correlation of 0.46 indicates that about 46.0% of current Sophia Genetics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.46 | |
| Spearman Rank Test | 0.35 | |
| Residual Average | 0.0 | |
| Price Variance | 0.09 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Sophia Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Sophia Genetics SA reported net income of (61.27 Million). This is 117.95% lower than that of the Health Care Equipment & Supplies sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 110.73% higher than that of the company.
Sophia Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sophia Genetics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sophia Genetics could also be used in its relative valuation, which is a method of valuing Sophia Genetics by comparing valuation metrics of similar companies.Sophia Genetics is currently under evaluation in net income category among its peers.
Sophia Genetics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Sophia Genetics from analyzing Sophia Genetics' financial statements. These drivers represent accounts that assess Sophia Genetics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Sophia Genetics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 779.7M | 132.0M | 305.0M | 202.0M | 232.2M | 220.6M | |
| Enterprise Value | 599.8M | (12.5M) | 200.3M | 151.8M | 174.5M | 165.8M |
Sophia Genetics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sophia Genetics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sophia Genetics' managers, analysts, and investors.Environmental | Governance | Social |
Sophia Genetics Institutional Holders
Institutional Holdings refers to the ownership stake in Sophia Genetics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Sophia Genetics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Sophia Genetics' value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 91.9 K | Silverberg Bernstein Capital Management Llc | 2025-06-30 | 45.7 K | Green Alpha Advisors, Llc | 2025-06-30 | 42.9 K | Citadel Advisors Llc | 2025-06-30 | 39.1 K | Pathstone Holdings Llc | 2025-06-30 | 36 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 35.2 K | Ridgewood Investments Llc | 2025-06-30 | 34.4 K | Dimensional Fund Advisors, Inc. | 2025-06-30 | 25.1 K | Renaissance Technologies Corp | 2025-06-30 | 20.7 K | Generation Investment Management Llp | 2025-06-30 | 6.8 M | Akre Capital Management, Llc | 2025-06-30 | 3.7 M |
Sophia Fundamentals
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.02) % | ||||
| Operating Margin | (0.92) % | ||||
| Current Valuation | 345.42 M | ||||
| Shares Outstanding | 67.85 M | ||||
| Shares Owned By Insiders | 6.43 % | ||||
| Shares Owned By Institutions | 49.58 % | ||||
| Number Of Shares Shorted | 31.51 K | ||||
| Price To Book | 5.99 X | ||||
| Price To Sales | 4.96 X | ||||
| Revenue | 65.17 M | ||||
| Gross Profit | 49.49 M | ||||
| EBITDA | (50.76 M) | ||||
| Net Income | (61.27 M) | ||||
| Cash And Equivalents | 216.61 M | ||||
| Cash Per Share | 3.38 X | ||||
| Total Debt | 30.03 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 7.58 X | ||||
| Book Value Per Share | 0.89 X | ||||
| Cash Flow From Operations | (42.82 M) | ||||
| Short Ratio | 0.44 X | ||||
| Earnings Per Share | (1.12) X | ||||
| Target Price | 7.33 | ||||
| Number Of Employees | 423 | ||||
| Beta | 1.11 | ||||
| Market Capitalization | 363.66 M | ||||
| Total Asset | 155.31 M | ||||
| Retained Earnings | (440.28 M) | ||||
| Working Capital | 72.6 M | ||||
| Net Asset | 155.31 M |
About Sophia Genetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sophia Genetics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sophia Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sophia Genetics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Sophia Genetics SA offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sophia Genetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sophia Genetics Sa Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sophia Genetics Sa Stock:Check out Sophia Genetics Piotroski F Score and Sophia Genetics Altman Z Score analysis. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sophia Genetics. If investors know Sophia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sophia Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share | Quarterly Revenue Growth 0.228 | Return On Assets | Return On Equity |
The market value of Sophia Genetics SA is measured differently than its book value, which is the value of Sophia that is recorded on the company's balance sheet. Investors also form their own opinion of Sophia Genetics' value that differs from its market value or its book value, called intrinsic value, which is Sophia Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sophia Genetics' market value can be influenced by many factors that don't directly affect Sophia Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sophia Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sophia Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sophia Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.